Loading
Five Prime Therapeutics developed bemarituzumab, an antibody aimed at a protein called FGFR2b that some stomach cancers carry in large amounts. Amgen bought the company in 2021.
Five Prime Therapeutics, Inc. (formerly Nasdaq: FPRX), of South San Francisco, was a clinical-stage company developing immuno-oncology and targeted cancer therapies. Its lead asset, bemarituzumab, is an antibody against FGFR2b, which the announcement says is overexpressed in about 30% of people with HER2-negative gastric cancer; the randomised, placebo-controlled phase 2 FIGHT trial in first-line advanced gastric or gastro-oesophageal junction cancer reported improvements in progression-free survival, overall survival and response rate. Amgen agreed on 4 March 2021 to buy Five Prime for USD 38 per share in cash, an equity value of about USD 1.9 billion, and the merger was completed on 16 April 2021.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · Amgen's announcement of 4 March 2021, filed as exhibit 99.1 to Five Prime's 8-K: USD 38.00 per share in cash, equity value of approximately USD 1.9 billion | 2021 | $1.9B | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2021-03-04 | Five Prime Therapeutics to Amgen Bemarituzumab, anti-FGFR2b antibody | Acquisition | not disclosed | $1.9bn | source |
Bemarituzumab is an antibody against FGFR2b, a growth receptor overproduced in about a third of stomach cancers. It improved survival early in its phase 3 trial, but the gain faded with longer follow-up.
Shares Bemarituzumab, FGFR2, Amgen, Monoclonal antibodies.
Shares Amgen, Monoclonal antibodies.
Shares Amgen, Monoclonal antibodies.
Shares Amgen, Monoclonal antibodies.
Shares Bemarituzumab, FGFR2, Gastric & gastro-oesophageal junction cancer.
Shares Bemarituzumab, FGFR2, Gastric & gastro-oesophageal junction cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/